|
Monday
|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
Sunday
|
|---|---|---|---|---|---|---|
|
0 events,
|
1 event,
Virtual Event
-
Virtual Event
The National Biodefense Science Board (NBSB) will convene to discuss the strategy and planning for the National Special Pathogen System and other high priority issues related to national public health emergency preparedness and response. The meeting is open to the public and will be held in a virtual format on September 28, 2021. The NBSB |
1 event,
Virtual Event
The Intelligence Advanced Research Projects Activity (IARPA) will hold a virtual Proposers’ Day for the TEI-REX Program (Targeted Evaluation of Ionizing Radiation Exposure) on September 29, 2021 from 10:00 am to 5:00 pm EDT with potential overflow into September 30, 2021 from 10:00 am to 1:00 pm. The TEI-REX Proposers’ Day meeting will be used |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
1 event,
Virtual Event
On Oct. 14 and 15, the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet to discuss the use of booster doses of the Moderna COVID-19 Vaccine and the Janssen COVID-19 Vaccine. Both vaccines are currently authorized for emergency use to prevent COVID-19 in individuals 18 years of age and older. The committee |
0 events,
|
0 events,
|
|
|
0 events,
|
0 events,
|
1 event,
Virtual Event
The CDC Advisory Committee on Immunization Practices will convene 20-21 October 2021. ACIP typically holds three meetings each year at CDC in Atlanta, Georgia to make vaccine recommendations. Due to the coronavirus disease 2019 (COVID-19) pandemic, ACIP meetings have been held more frequently and have been virtual only (no in-person attendance). The agenda will include |
0 events,
|
0 events,
|
0 events,
|
|
|
0 events,
|
1 event,
Virtual Event
The FDA anticipates receiving a request from Pfizer to amend its emergency use authorization to allow the use of its COVID-19 vaccine in children 5 through 11 years of age. In anticipation of the request, the FDA is scheduling an Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Oct. 26 to inform the |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
